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Stress-inducible phosphoprotein 1 has unique
cochaperone activity during development and
regulates cellular response to ischemia via the prion
protein
Flavio H. Beraldo,*,† Iaci N. Soares,*,‡,# Daniela F. Goncalves,*,** Jue Fan,*
Anu A. Thomas,*,† Tiago G. Santos,†† Amro H. Mohammad,*,‡ Martin Roffé,††
Michele D. Calder,†,§,‡‡ Simona Nikolova,* Glaucia N. Hajj,†† Andre L. Guimaraes,*,§§
Andre R. Massensini,** Ian Welch,储 Dean H. Betts,†,‡‡ Robert Gros,*,†
Maria Drangova,*,¶ Andrew J. Watson,†,§,‡‡ Robert Bartha,*,¶ Vania F. Prado,*,†,‡,1
Vilma R. Martins,††,1,2 and Marco A. M. Prado*,†,‡,1,2
*Robarts Research Institute, †Department of Physiology and Pharmacology, ‡Department of Anatomy
and Cell Biology, §Department of Obstetrics and Gynaecology, 储Animal Care and Veterinarian
Services, and ¶Department of Medical Biophysics, University of Western Ontario, London, Ontario,
Canada; #Program in Molecular Medicine and **Department of Physiology and Biophysics, Federal
University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil; ††Department of Molecular and
Cell Biology, International Research Center, A. C. Camargo Cancer Center and National Institute for
Translational Neuroscience, São Paulo, Brazil; ‡‡Children’s Health Research Institute–Lawson Health
Research Institute, London, Ontario, Canada; and §§University of Montes Claros, Montes Claros,
Minas Gerais, Brazil
Stress-inducible phosphoprotein 1 (STI1) is
part of the chaperone machinery, but it also functions
as an extracellular ligand for the prion protein. However, the physiological relevance of these STI1 activities
in vivo is unknown. Here, we show that in the absence of
embryonic STI1, several Hsp90 client proteins are
decreased by 50%, although Hsp90 levels are unaffected. Mutant STI1 mice showed increased caspase-3
activation and 50% impairment in cellular proliferation. Moreover, placental disruption and lack of cellular viability were linked to embryonic death by E10.5 in
STI1-mutant mice. Rescue of embryonic lethality in
these mutants, by transgenic expression of the STI1
gene, supported a unique role for STI1 during embryonic development. The response of STI1 haploinsufficient mice to cellular stress seemed compromised, and
mutant mice showed increased vulnerability to ischemic
insult. At the cellular level, ischemia increased the
secretion of STI1 from wild-type astrocytes by 3-fold,

ABSTRACT

Abbreviations: BAC, bacterial artificial chromosome; CM,
conditioned medium; DIV, days in vitro; GRK2, G-proteincoupled receptor kinase 2; H&E, hematoxylin and eosin;
HOP, heat-shock organizing protein; Hsp70, heat-shock protein
70; Hsp90, heat-shock protein 90; MCAO, middle cerebral artery
occlusion; MEF, mouse embryonic fibroblast; micro-CT, microcomputed tomography; MRI, magnetic resonance imaging;
OGD, oxygen and glucose deprivation; p53, protein 53; Piwi,
P-element-induced wimpy testis; PrPC, prion protein; STAT3,
signal transducer and activator of transcription 3; STI1, stressinducible phosphoprotein I; Stip1, mouse stress-inducible phosphoprotein I; TPR, tetratricopeptide repeat
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whereas STI1 haploinsufficient mice secreted half as
much STI1. Interesting, extracellular STI1 prevented
ischemia-mediated neuronal death in a prion proteindependent way. Our study reveals essential roles for
intracellular and extracellular STI1 in cellular resilience.—Beraldo, F. H., Soares, I. N., Goncalves, D. F.,
Fan, J., Thomas, A. A., Santos, T. G., Mohammad,
A. H., Roffe, M., Calder, M. D., Nikolova, S., Hajj,
G. N., Guimaraes, A. N., Massensini, A. R., Welch, I.,
Betts, D. H., Gros, R., Drangova, M., Watson, A. J.,
Bartha, R., Prado, V. F., Martins, V. R., and Prado,
M. A. M. Stress-inducible phosphoprotein 1 has unique
cochaperone activity during development and regulates
cellular response to ischemia via the prion protein.
FASEB J. 27, 000 – 000 (2013). www.fasebj.org
Key Words: Hsp90 䡠 stroke 䡠 maternal-effect gene 䡠 Hsp70 䡠
prion protein
The chaperones heat-shock protein 90 and 70
(Hsp90 and Hsp70) cooperate to assist the folding and
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stability of many client proteins that are critical for
cellular homeostasis (1, 2). Cochaperones are thought
to play important roles in assisting Hsp70 and Hsp90
(3). The cochaperone stress-inducible phosphoprotein
1 [STI1; or heat-shock organizing protein (Hop)] is
thought to participate in different aspects of cellular
function (4). The protein contains 3 tetratricopeptide
repeat (TPR)-containing domains (TPR1, TPR2A, and
TPR2B), which allows simultaneous binding to Hsp70
and Hsp90 (5). These observations led to the hypothesis that STI1 acts as an adaptor protein to transfer
client substrates between Hsp70 and Hsp90. Indeed,
STI1 can regulate the ATPase activity of Hsp90 to help
drive the sequential steps of the chaperone machinery
(6). Recent structural work suggests that STI1 can
maintain Hsp90 in an open conformation to receive
client proteins recruited by Hsp70 (7). STI1 may also
function as a scaffolding protein, for example, by
linking Hsp90 to P-element-induced wimpy testis (Piwi),
a process that regulates phenotype canalization in
Drosophila (8).
STI1, similar to heat-shock proteins (9, 10), can also
be secreted by cells. The protein is secreted by astrocytes via microvesicles exerting extracellular effects on
neurons and astrocytes (11–13). Extracellular STI1 can
form a signaling complex with the prion protein (PrPC)
in hippocampal neurons to activate cellular signaling
by increasing intracellular calcium via ␣7 nicotinic ACh
receptors (␣7nAChRs; ref. 14). In other types of neurons, STI1 can also increase intracellular Ca2⫹ in a
manner that is independent of ␣7nAChRs (15). STI1/
PrPC engagement can protect hippocampal neurons
against staurosporine-mediated cell death and also increase their differentiation (4, 16, 17).
Elimination of STI1 does not affect growth in yeast,
unless in the presence of Hsp90 mutants (18). In
Caenorhabditis elegans, lack of STI1 is not lethal, but it
decreases life span and increases sensitivity to stress
(19). A number of cochaperones containing TPR domains, similar to those in STI1, interact with the
MEEVD motif of Hsp90 (5); hence, it is possible that
other cochaperones could substitute for STI1. In mammals, the in vivo roles of STI1 are not understood.
Here, we targeted STI1 in mice and found that this
protein is expressed early during development. Embryonic STI1 deficiency impairs survival of mice, and we
show that several Hsp90 client proteins are reduced in
STI1 mutant mice, suggesting that multiple Hsp90
clients may be affected in the absence of STI1. Early
embryonic death of STI1-mutant mice could be rescued
by transgenic expression of STI1, confirming that STI1
has unique cochaperone activity in mice. In adult mice,
reduced levels of STI1 affected the response to cellular
stress, demonstrated by the increased sensitivity of STI1
haploinsufficient mice to ischemic insult. We provide
evidence that extracellular STI1 supports neuronal
survival following ischemia and that this neuroprotective effect is lost in PrPC-null neurons. These data
suggest that STI1 is a multifunctional protein required
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during development, and in the absence of STI1, cells
have decreased resilience to stress.

MATERIALS AND METHODS
Mouse line generation
Genetically modified mice were generated using standard
homologous recombination techniques (20), using C57BL/6J ES
cells. Mice were generated by Ozgene (Perth, Australia).
Construct design is shown in Supplemental Fig. S1A. Chimeric mice were bred to C57BL/6J mice, and germline transmission of the mutant STI1 allele was identified by Southern
blot (not shown). F1 mice were then crossed to constitutive
Cre mice to remove loxP-flanked regions. Cre-recombined
mice were then crossed to C57BL/6J mice, and progeny
bearing the recombined STI1 allele, but lacking the Cre
transgene, was identified by Southern blot analysis (not
shown). These mice were then used to expand the colony.
STI1⫺/⫹ mice were then intercrossed to generate STI1⫺/⫺
mice. We have attempted to generate mice with a conditional
STI1-floxed allele; however, we found that after removal of
the neocassete, this particular floxed allele was null and also
caused embryonic lethality (results not shown).
The BMQ-41A8 bacterial artificial chromosome (BAC), a
56,549-bp DNA fragment from mouse chromosome 19 containing the STI1 gene, was obtained from Source BioScience
Life Sciences (Nottingham, UK). The BAC was digested and
analyzed using restriction enzymes. This BAC was then used
to generate transgenic mice using standard techniques at the
Jackson Laboratories (Bar Harbor, ME, USA) transgenic
facility in a C57BL/6J background. In all experiments that
involved quantification between genotypes, the experimenters were blinded to the genotypes.
Ethics statement
Animals were maintained and handled by the University of
Western Ontario Animal Care and Veterinarian Service, or in
the A. C. Camargo Hospital vivarium. Procedures were conducted in accordance with approved animal use protocols at
the University of Western Ontario (2008/127) and the A. C.
Camargo Hospital (037/09), and they were in accordance
with the Canadian Council of Animal Care (CCAC) and U.S.
National Institutes of Health (NIH) guidelines.
Isolation of blastocysts and embryos
Heterozygous STI1 females, aged 4 to 5 wk, were superovulated (5 IU of pregnant mare serum gonadotropin followed
48 h later by 5 IU human chorionic gonadotropin) and mated
with heterozygous STI1 males. Females were euthanized 3.5 d
later, and the blastocysts were collected by uterine flushing
using M2 medium (Sigma, Oakville, ON, Canada). Embryos
were collected from timed pregnant females and were genotyped.
RT-PCR and qPCR
Samples [brain tissue, mouse embryos (E10) and astrocyte
cultures] were homogenized in TRIzol, and total RNA was
extracted using the Aurum Total RNA for fatty and fibrous
tissue kit from Bio-Rad (Hercules, CA, USA). qRT-PCR and
qPCR were performed as described previously (21, 22). A
nontemplate reaction was used as a negative control for each
experiment, and ␤-actin mRNA levels were used to normalize
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the data, as described previously. Sequences of primers used
are shown in Supplemental Table S1.
Astrocyte primary culture
Astrocyte primary cultures were prepared as described previously (11). Briefly, cortical tissue from each individual embryo was dissociated in 5 ml DMEM supplemented with 1%
(v/v) penicillin/streptomycin and 10% FBS and plated in a
100-mm cell culture dish. Cultures were maintained in an
incubator at 37°C, 5% CO2 for 10 –12 d, and the medium was
replaced 1⫻/wk.
Neuronal culture
Primary cultures of hippocampal neurons from E17 pregnant
females were obtained as described previously (17). Cultures
from individual embryos were maintained separately. Neuronal cultures from control and PrPC-null mice were prepared
as described previously (14).
Mouse embryonic fibroblast (MEF) culture
MEFs were prepared from E10.5 embryos as described previously (23). The cultures were obtained from each embryo,
and the heads were used for genotyping. For survival curves,
2 ⫻ 104 cells were plated in duplicate into 24-well plates; to
one of them, we added DMEM supplemented with 20% FBS,
and to the other, we added half of the volume of the same
medium with 40% of FBS and half of 2⫻ concentrated
conditioned medium (CM) from STI1⫹/⫹ MEFs. The medium was supplemented with recombinant STI1 (2 M).
Western blot analysis
Samples were homogenized in ice-cold RIPA buffer (50 mM
Tris-HCl, pH 8; 150 mM NaCl; 1% Nonidet P-40; 1% sodium
deoxycholate; and 1% SDS), and the protein concentration
was evaluated using protein assay reagent (Bio-Rad, Hercules,
CA, USA). Protein (5–20 g) was loaded on each gel lane and
transferred to membrane for Western blot analysis, as described previously (21). All blots were quantified using FluoChem (Alpha Innotech; GE Healthcare, London, ON, Canada) or ImageJ software (NIH, Bethesda, MD, USA).
Oxygen and glucose deprivation (OGD)
Neurons were plated in P35 (5⫻105 cells) dishes, and the
cultures were kept under the conditions described above
until the medium was changed after 7 days in vitro (DIV).
Cells were submitted to OGD by using a chamber to control
the levels of oxygen (0.5%) and CO2 (5%) for 1 h, and the
neurons were kept in glucose-deficient neurobasal medium
just prior to the hypoxia treatment. After OGD, the glucosefree medium was replaced with regular medium with or
without recombinant STI1 (1 M), and the cells were returned to normal oxygen conditions for 24 h.
Astrocytes were plated in P35 dishes. After 70% of confluence, the cells were deprived of FBS for 48 h, after which a
medium change was performed. Astrocytes were submitted to
OGD in glucose-deficient DMEM. For the secretion experiments, medium was collected after 9 h of OGD. In control
cells, medium was collected after 9 h of incubation, as
described below, and used in Western blots to detect secreted
STI1. For the cell death assay, glucose-free medium was
replaced with regular medium, and cells were returned to
normal oxygen conditions for 48 h.
STI1 AND CELLULAR STRESS

Secretion of STI1 in CM
Astrocytes or fibroblasts were plated in P60 dishes as described above. After 90% of confluence, the cells were
deprived of FBS for 48 h. Culture medium was then collected
and centrifuged at 10,000 g for 20 min at 4°C, and the
supernatant was used as CM.
Micro-computed tomography (micro-CT)
For micro-CT, embryos were harvested at E10.5 and fixed in
10% formalin in PBS (48 h at 4°C), then immersed in Lugol
solution (10 g KI plus 5 g I in 400 ml dH2O) for 48 h (24).
The Lugol solution acted as a micro-CT contrast agent.
Scanning was performed using a GE Locus SP scanner (GE
Healthcare) using the following scan parameters: 80 kVp with
0.508-ml Al filtration, 80 A, 900 views over 360°; 4 frames
averaged, with images reconstructed to yield 13-m isotropic
voxels (25).
Hematoxylin and eosin (H&E) staining
Embryos (E10.5) were harvested, formalin fixed (10% formalin for 48 h at 4°C), and paraffin embedded. Sections (3–5
m) were deparaffinized and stained with H&E. Images were
acquired with an Olympus DP72 camera using cellSens Dimension software (Olympus, Tokyo, Japan).
Immunofluorescence
Astrocytes (1⫻105 cells) and fibroblasts (1⫻105 cells) were
grown on coverslips. Cells were fixed in 4% paraformaldehyde/PBS for 20 min and washed in PBS Triton X-100
(0.05%) solution followed by blocking in PBS with 0.05%
TritonX-100 plus 10% of normal goat serum. Cells were
incubated with anti-STI1 (1:400), anti-Hop (1:100; Enzo Life
Sciences, Farmingdale, NY, USA), anti-STI1 (1:100; Sigma),
anti-␤-tubulin (1:100; Sigma), or anti-␥-H2AX (1:100; Cell
Signaling, Boston, MA, USA) overnight at 4°C.
The deciduae containing E6.5 embryos were dissected,
fixed overnight at 4°C in 4% paraformaldehyde, and cryoprotected with 0.1 M phosphate buffer (pH 7.4) containing 30%
sucrose. Whole deciduae were frozen with dry ice, and
cryostat sections (10 m) were obtained and mounted on
silanized slides. E10.5 embryos were harvested, formalin fixed
(10% formalin for 48 h at 4°C), and paraffin embedded.
Sections (3–5 m) were deparaffinized. For immunofluorescence, tissues were incubated with blocking solution (0.1 M
phosphate buffer, pH 7.4, containing 0.2% Triton X-100 plus
20% goat serum) for 1 h at room temperature, followed by
overnight incubation with anti-rabbit STI1 antibody (1:200)
or anti-rabbit caspase 3 activated (1:200). Tissues were washed
3⫻ with PBS and anti-rabbit Alexa Fluor 488 plus TO-PRO3
iodide (1:1000) or Hoechst (1:1000) for nuclei staining for 1
h at room temperature. Slides were mounted on coverslips
using Fluorsave (Calbiochem, La Jolla, CA, USA) and imaged
using a Leica TCS SP5 II laser scanning confocal system or
Zeiss LSM-510 confocal microscope (Carl Zeiss, Oberkochen,
Germany).
Cell death assay
Neuronal and astrocyte cell death assays were performed
using the Live/Dead viability/cytotoxicity kit for mammalian
cells (Invitrogen, Oakville, ON, Canada) as described in the
manual. Counting was done using ImageJ software and cal3

culated as percentage of dead cells [number of dead cells/
(number of dead cells ⫹ viable cells) ⫻ 100].
Middle cerebral artery occlusion (MCAO)
Anesthesia was induced by inhalation of 4% isoflurane (in
O2), and maintenance was done by inhalation of 1.5%
isoflurane. A modification of a previously described method
(26) for transient intraluminal MCAO was used. Under an
operating microscope, a monofilament nylon suture (diameter 0.06-0.09 mm; Doccol Corp., Redlands, CA, USA) was
inserted through the left common carotid artery into the
internal carotid artery and then into the circle of Willis,
effectively occluding the MCA for 60 min. Sham-treated
animals underwent the same procedure, with the exception
of the advancement of the filament to occlude the cerebral
artery. After filament insertion, the mice were removed from
anesthesia and kept at 37°C under a heat lamp freely moving
during 1 h of occlusion. Mice were then anesthetized again,
and the filament was quickly removed. At 1 h after surgery,
mice were injected i.p. with saline to maintain hydration. This
procedure was repeated again, if necessary, on the basis of
weight recovery of the animal and clinical assessment score.
Food pellets were wetted and kept on the floor of the cage for
recovering mice. Neurological assessment was performed 1,
24, and 48 h after surgery following scores modified from the
5-point Bederson scale (27): 0, no deficit; 1, mild forelimb
weakness; 2, severe forelimb weakness, consistent turns to the
deficit side when lift by the tail; 3, compulsory circling; 4,
unconscious; 5, dead. Only mice that scored 2 or 3 were used
in the experiments. Heart rate data were obtained under
baseline and during the MCAO period (30 min postocclusion) in conscious mice using the CODA computerized
noninvasive system (Kent Scientific, Torrington, CT, USA).
Rectal temperature was monitored by a homeothermic blanket control unit (Harvard Apparatus, Holliston, MA, USA).
Arterial blood samples (obtained via cardiac puncture under
isoflurane anesthesia) were taken at baseline or at the end of
the MCAO period and analyzed for pH and glucose using a
blood analyzer (ABL-725; Radiometer, Copenhagen, Denmark).
Magnetic resonance imaging (MRI)
An Agilent (Palo Alto, CA, USA) 9.4-T small-animal horizontal-bore MRI system was used to acquire images of the mouse
brain 24 h after MCAO. Two imaging sequences were used to
visualize tissue damage due to ischemia: a T2-weighted 2-dimensional fast spin echo (FSE) sequence (TE⫽45 ms, TR⫽
3000 ms, FOV 19.2⫻19.2 mm, 31 slices, slice thickness⫽500
m, acquisition matrix 128⫻128) and a 3-dimensional bal-

anced steady-state free precession (bSSFP) sequence (TE⫽3.7
ms, TR⫽7.4 ms, FOV 19⫻16⫻13 mm, acquisition matrix
154⫻132⫻102). Infarct volume was measured by manual
tracing of the hyperintense tissue in each slice of the T2
images using ImageJ by a single investigator blinded to the
genotypes (D.G.).
Adhesive removal
Postischemic and sham-treated animals were subjected to
behavioral tests 7 d after stroke. The adhesive removal test is
sensitive to unilateral somatosensory dysfunction and was
used to determine functional recovery (28). Three trials were
conducted and averaged per day. Individual trials were separated by at least 15 min.

RESULTS
Mouse STI1 (Stip1) deficiency causes embryonic
lethality
To uncover potential in vivo roles of STI1 in mammals,
we generated a Stip1-knockout mouse line (Supplemental Fig. S1A). The strategy used the Cre/Lox system to
remove exons 2 and 3 from a floxed Stip1 allele. This
deletion truncated the STI1-coding region and created
a stop codon close to the initial ATG, so that the
protein expression was abolished. Sequencing of the
targeted Stip1 allele (STI1⫺) confirmed the genetic
manipulation. We found that embryos containing 2
Sti1⫺ alleles died around E9.5–E10.5 (Table 1). Further
analysis of STI1⫹/⫺ intercrosses revealed that recovery
of STI1⫺/⫺ embryos did not follow Mendelian frequency. The reduced frequency observed (9 and 12%
instead of 25% for E3.5 and E10.5, respectively; Table
1), suggested that STI1 deficiency affected the survival
of embryos prior to implantation.
To test the possibility that STI1 is expressed early
during development, we immunolabeled blastocysts
(E3.5) with a STI1 antibody. Immunoreactivity for STI1
was easily detected in blastocysts. Surprisingly, substantial labeling for STI1 was also detected in STI1⫺/⫺
blastocysts, although at lower levels than observed in
wild-type blastocysts (Fig. 1A). Similar results were
obtained with two other commercial STI1 antibodies
(not shown). All blastocysts had their genotypes con-

TABLE 1. Viability analysis of STI1⫺/⫺ mice and embryosa
Number with genotype
Stage

Live birth
E17.5
E13.5
E10.5
E3.5

⫹/⫹

STI1

65
33
14
68
47

⫺/⫹

STI1

103
42
22
131
57

STI1⫺/⫺

Reabsorbed

Total

0***
0***
0***
27 (12%)a,***
16 (13%)a,*

0
21
16
68
0

168
96
52
294
120

Genotypes were determined by PCR as described in Materials and Methods. Empty deciduas were
scored as reabsorbed.aSTI1⫺/⫺ ratio. Data were analyzed by 2 test, comparing the expected and
observed frequencies for each genotype at different time points of embryonic development. *P ⱕ 0.05,
***P ⱕ 0.0005.
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Figure 1. Expression of STI1, Oct4, and CDX2 in mouse blastocysts. A) STI1
labeling (green) in STI1⫹/⫹, STI1⫺/⫹, and STI1⫺/⫺ blastocysts (representative
images of 24 STI1⫹/⫹, 22 STI1⫹/⫺, and 8 STI1⫺/⫺ blastocysts). Nucleus is shown
in blue. Scale bars ⫽ 20 m. B) Agarose gel showing an example of blastocyst
genotyping. C) Control experiments for STI1 antibody specificity. Antibody was
incubated (bottom panels) or not (upper panels) with recombinant STI1 and
then used to label STI1⫹/⫹ blastocysts. D) Labeling for the pluripotency marker
Oct4 (green) in STI1⫹/⫹, STI1⫺/⫹, and STI1⫺/⫺ blastocysts (representative
images of 13 STI1⫹/⫹, 23 STI1⫺/⫹, and 4 STI1⫺/⫺). E) Labeling for marker of
trophoblast-committed cells, CDX2 (green), in STI1⫹/⫹, STI1⫺/⫹, and STI1⫺/⫺
blastocysts (representative images of 13 STI1⫹/⫹, 25 STI1⫺/⫹, and 5 STI1⫺/⫺).
Scale bars ⫽ 20 m.

firmed by PCR after immunostaining (Fig. 1B). Control
experiments showed that immunolabeling with the
STI1 antibody was completely abolished by absorption
with excess recombinant STI1 (Fig. 1C), indicating that
STI1 labeling in blastocysts was specific. Since there are
no other STI1 homologs, these results suggest that
maternal STI1, deposited either as protein or mRNA, is
present in blastocysts and may play a role in early
embryonic development.
Given the early expression of STI1 in blastocysts and
lethality of STI1⫺/⫺ embryos, we tested whether genes
critical for embryonic development might be altered in
blastocysts. We did not observe a difference in the
expression of the pluripotency marker Oct4 between
wild-type and STI1⫺/⫺ blastocysts (Fig. 1D; all blastocysts were genotyped for STI1 alleles after immunostaining). Moreover, CDX2 labeling, used to probe for
trophoblast-committed cells, was similarly expressed in
control and STI1-deletion mutants (Fig. 1E).
Immunoblot analysis of individual embryos at the last
developmental stage in which we could find STI1⫺/⫺
mice (E10.5) demonstrated that protein extracts (5 g
of protein) from STI1⫺/⫹ embryos showed 50% reduction in STI1 levels, while no STI1 immunoreactivity was
observed in STI1⫺/⫺ extracts (Fig. 2A). However, when
we loaded the gel with a higher amount of protein (20
g), we were able to detect small quantities of STI1 in
STI1⫺/⫺ extracts (20%; Fig. 2B). Moreover, by immunofluorescence, we observed weak immunolabeling for
STI1 in sections of STI1⫺/⫺ embryos (E10.5; Fig. 2C).
STI1 AND CELLULAR STRESS

We quantified STI1 mRNA in STI1⫺/⫺ E10.5 embryos
by RT-PCR and qPCR. Our results shown that no STI1
mRNA is present in STI1⫺/⫺ E10.5 embryos (Fig. 2D),
suggesting that the immunoreactivity that we detected
in embryos might originate from extraembryonic sites.
Interestingly, we found high levels of STI1 present at
extraembryonic sites in wild-type embryos, specifically
at the trophoblast layer (Fig. 2E). Whether this extraembryonic STI1 may contribute for survival of mutant
embryos during the early developmental stage is currently unknown. In addition, we observed the presence
of acute inflammation in and around the labyrinth in
the placenta from STI1⫺/⫺ embryos (Fig. 2F), suggesting that their placenta has had a vascular disruption, as
there was no evidence of infection. Hence, placental
disruption might facilitate the transfer of maternal
STI1 to embryos but could also contribute to embryonic dysfunction. STI1 has been shown to be secreted
by distinct cell types (11, 29, 30), including ovarian cells
(31, 32) and has also been found in plasma (31).
To understand the characteristics of embryonic
development in STI1-mutant mice, we performed
micro-CT analysis. This experiment demonstrated
that neural tube and limb buds were poorly formed
in STI1⫺/⫺ embryos (Fig. 3A). In addition, histochemistry analysis showed that STI1⫺/⫺ embryos
presented a great number of cells that were undergoing apoptotic cell death, characterized by increased levels of activated caspase-3 (Fig. 3B), as well
5

Figure 2. STI1 expression in embryos. A, B) Western blot analysis of STI1 in STI1⫹/⫹, STI1⫺/⫹, and STI1⫺/⫺ embryos at E10.5
(5 and 20 g of protein, respectively; protein extracts from 5 embryos for each genotype in A and 4 embryos for each genotype
in B). Molecular mass markers are shown on the side; actin was used as a loading control. C) Immunofluorescence analysis of
STI1 expression (green) in STI1⫹/⫹ and STI1⫺/⫺ in mouse embryos (E10.5). Nuclei were stained with the nuclear marker Hoechst
(blue). Scale bars ⫽ 20 m. D) STI1 mRNA expression by RT-PCR (top gel) and qRT-PCR (bar graph) in ST1⫹/⫹, STI1⫺/⫹, and
STI1⫺/⫺ embryos (E10.5; n⫽4 embryos/genotype). E) Immunofluorescence of STI1⫹/⫹ mouse embryo (E6.5) showing high
levels of STI1 (green) at extraembryonic sites (arrows). Note that STI1 staining in STI1⫹/⫹ embryo is much stronger than in
deciduas (tissue from STI1⫺/⫹ mother). Nuclei were stained with the nuclear marker TO-PRO (red). Scale bars ⫽ 75 m.
F) Placental staining using H&E from E10.5 STI1⫺/⫺ mouse embryos (representative H&E images from 2 embryos/genotype).
Scale bars ⫽ 200 m.

as pyknotic apoptotic bodies with a hypereosinophilic cytoplasm in H&E (Fig. 3C–H).
The early embryonic death with increased apoptosis
in STI1-mutant mice is unexpected, given that elimination of STI1 in yeast (32) and C. elegans is not lethal
(19). To test the possibility that the cochaperone

activity of STI1 is required during development, we
examined the expression levels of 3 distinct Hsp90
client proteins. Immunoblot analysis showed that Hsp90
levels were unchanged in STI1⫺/⫺ mice (Fig. 4A, B). In
contrast, the levels of G-protein-receptor kinase 2
(GRK2), signal transducer and activator of transcrip-

Figure 3. Embryonic STI1 deficiency affects development.
A) Micro-CT analysis of STI1⫹/⫹, STI1⫺/⫹, and STI1⫺/⫺
mouse embryos (E10.5). Micro-CT images (bottom panel) were used for 3-dimensional reconstruction of embryos; images
in top and middle panels are surface renderings showing different angles (representative images of 4 embryos/genotype).
B) Levels of activated caspase-3 (green) in E10.5 tissue. C–H) Morphological analyses of E10.5 embryos stained with H&E
showing elevated number of cells with pyknotic nuclei and hypereosinophilic cytoplasm, indicating apoptotic cells in
STI1⫺/⫺ embryos (arrows indicate pyknotic nuclei; representative images of 3 embryos/genotype). Scale bars ⫽ 200 m
(A); 500 m (C, F); 50 m (B–G).
6
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Figure 4. Analysis of protein expression in STI1⫺/⫺ E10.5 embryos. A) Western blot analysis of Hsp90, GRK2, p53, and STAT3
in STI1⫹/⫹ and STI1⫺/⫺ embryos at E10.5 (20 g protein). B) Quantification of protein expression from Western blots (protein
extracts from 4 embryos/genotype for GRK2 and p53; 7 embryos/genotype for Hsp90 and STAT3). Results are presented as
means ⫾ se. *P ⬍ 0.01, **P ⬍ 0.001; Student’s t test.

tion 3 (STAT3), and protein 53 (p53), all Hsp90 client
proteins (33–35) were significantly reduced to almost
50% (Fig. 4A, B).
To further understand the consequences of interference with Stip1 for cellular function, we cultured
MEFs from E10.5 embryos. During the initial days in
culture, we could not distinguish wild-type from
STI1⫺/⫺ cells using morphological criteria. However,
after a few days, we noticed that STI1⫺/⫺ MEFs were
dying, whereas wild-type or STI1⫺/⫹ MEFs thrived
well in culture (Fig. 5A, B). Interestingly, most STI1⫺/⫺
MEFs had died off following 8 –10 d in culture (Fig. 5A,
B). To understand potential causes of this increased
lethality in STI1⫺/⫺ MEFs, we labeled these cells during
the first 2 d of culture with an antibody against ␥-H2AX,
a phosphorylated histone recruited to sites of DNA
double-strand breaks in response to distinct cellular
stresses (36). Wild-type MEFs showed no labeling for
␥-H2AX (Fig. 5C); however, STI1⫺/⫺ MEFs presented
widespread nuclear foci labeling (Fig. 5C), suggestive of
increased cellular stress levels. Interestingly, STI1⫺/⫹
MEFs also presented ␥-H2AX labeling (Fig. 5C). Since
enhanced cellular stress levels increase DNA damage,
which may affect cell cycle (37), we examined proliferation of STI1⫺/⫺ MEFs and found decreased proliferation, as compared to STI1⫺/⫹ or STI1⫹/⫹ MEFs (Fig.
5D). Hence, STI1⫺/⫺ MEFs were impaired in cellular
proliferation and showed increased levels of cellular
stress, which likely affected cellular viability.
We examined STI1 expression in MEFs and found
that STI1⫺/⫺ MEFs presented weak nuclear immunolabeling for STI1 (Fig. 5C). Immunolabeling in STI1⫺/⫺
MEFs was specific because the same pattern of STI1
immunolabeling was observed with distinct antibodies
(Supplemental Fig. S1B); STI1 immunolabeling in
MEFs and other cells could be absorbed with excess
recombinant STI1 (Supplemental Fig. S1C); and the
main antibody that we used in these experiments
recognizes only one band in immunoblots with the
correct molecular mass in embryos or in brain extracts
of adult STI1⫹/⫹ and STI1⫺/⫹ mice (Fig. 2A, B and
Supplemental Fig. S1D). Hence, it is likely that MEFs
STI1 AND CELLULAR STRESS

containing some maternal STI1 may have been selected
to survive longer in these cultures.
The weak STI1 labeling was concentrated mostly in
the nucleus in STI1⫺/⫺ MEFs (Fig. 5C), as opposed
to the predominantly cytoplasmic labeling observed
in wild-type MEFs and in blastocysts (see Fig. 1A).
Fibroblasts obtained from STI1⫺/⫹ MEFs, which presented overall weaker labeling than wild-type MEFs,
also showed increased nuclear labeling for STI1 (Fig.
5C). This increased level of nuclear STI1 is likely
related to increased levels of cellular stress, as stress has
been shown to increase nuclear accumulation of STI1
(38). STI1 has been previously shown to have a nuclear
localization signal (NLS; refs. 38, 39). Given that wildtype MEFs secrete STI1 (Fig. 5F), we examined whether
increasing levels of extracellular STI1 could perhaps
attenuate the lethality observed in STI1⫺/⫺ MEFs. We
incubated STI1⫺/⫺ MEFs with CM obtained from wildtype MEFs supplemented with 2 M recombinant STI1
(Fig. 5E). Lethality of STI1⫺/⫺ MEFs could not be
rescued by increasing extracellular levels of STI1 or by
other factors secreted by wild-type MEFs in this condition. This result suggests that extracellular STI1 is not
sufficient to maintain mutant MEFs viability.
Rescue of lethality in STI1ⴚ/ⴚ mice
Given the presence of small amounts of extraembryonic STI1 in STI1-mutant mice, we decided to test
further the requirement for embryonic STI1 during
development. For this experiment, we initially generated STI1 transgenic mice, which were crossed with
STI1⫺/⫹, and tested for rescue of lethality of STI1⫺/⫺
mice. Since STI1 appears to be required prior to
implantation for survival of blastocysts, we used BAC
containing the STI1 gene to generate transgenic mouse
lines and reproduce any required early expression of
STI1 during embryogenesis. We generated two distinct
lines of STI1 BAC transgenic mice (STI1-TgA and
STI1-TgC) presenting 10 and 2 extra alleles of STI1,
respectively, as determined by qPCR (Fig. 6A). STI1
mRNA levels were increased 5-fold in STI1-TgA line
compared to wild-type littermates (Fig. 6B), and pro7

Figure 5. Survival and stress levels of STI1⫺/⫺ MEFs. A) Images
of MEFs obtained from STI1⫹/⫹, STI1⫺/⫹, and STI1⫺/⫺
embryos (E10.5) at d 3 and 7 in culture (representative
images of MEF cultures obtained from embryos: 32
STI1⫹/⫹, 67 STI1⫺/⫹, and 13 STI1⫺/⫺). Scale bars ⫽ 100
m. B) MEF survival curves (32 STI1⫹/⫹, 67 STI1⫺/⫹, and
13 STI1⫺/⫺). C) Expression of STI1 (green) and ␥-H2AX
(red) in MEFs (representative images of MEFs obtained from independent cultures of 4 embryos/genotype). Scale bars ⫽
20 m. D) Cellular proliferation determined by BrdU staining (green) in STI1⫹/⫹, STI1⫺/⫹, and STI1⫺/⫺ MEFs
(independent cultures from 5 embryos/genotype). Scale bars ⫽ 20 m. Top panel: representative images. Bottom panel:
quantification of BrdU-positive cells. E) Survival curves of STI1⫺/⫺ MEFs growing in STI1⫹/⫹ CM supplemented with 2 M
recombinant STI1 (independent MEF cultures from 5 STI1⫺/⫺ embryos). F) STI1 secretion by STI1⫹/⫹ MEFs. Survival
curves were analyzed by log-rank test (Mantel-Cox; P⫽0.0001 between STI1⫹/⫹, and STI1⫺/⫺). Cellular proliferation is
presented as means ⫾ se. ***P ⬍ 0.0001; 1-way ANOVA and Neuman-Keuls post hoc test.

tein level was also increased 4-fold in this transgenic
line (Fig. 6C). In contrast, STI1-TgC line did not show
increased levels of STI1 mRNA or protein (Fig. 6B, D),
suggesting that in this second transgenic mouse line the
BAC is transcriptionally silent. We crossed STI1-TgA
and STI1-TgC lines with STI1⫺/⫹, and then we interbred their offspring. We could not detect STI1⫺ alleles
in crosses of STI1-TgC (0 STI1⫺/⫺ TgC pups out of 44
pups born from STI1⫹/⫺TgC⫹ ⫻ STI1⫹/⫺TgC⫺ breeding), supporting the notion that this line did not
express BAC-derived STI1. In contrast, STI1-TgA BAC
expression was sufficient to rescue STI1⫺/⫺ mice (11
STI1⫺/⫺ TgA pups out of 52 pups born from STI1⫹/⫺
TgA⫹ ⫻ STI1⫹/⫺TgA⫺ breeding). Figure 6E shows the
presence of STI1⫺ alleles in adult mice from STI1-TgA
crosses detected by qPCR.
Decreased levels of STI1 increased cellular stress and
vulnerability to ischemia
During development, the absence of embryonic STI1
increased cellular stress and vulnerability of cells. To
determine whether altered levels of STI1 influence
cellular resilience, we investigate stress levels in astrocytes. STI1⫺/⫹ astrocytes showed ⬃50% decrease in
STI1 levels (Fig. 7A), and they secreted less STI1 than
their control counterparts (Fig. 7B). As observed for
STI1⫺/⫹ MEFs (and also for STI1⫺/⫺ MEFs), STI1 was
present mainly in the nucleus of a large number of
STI1⫺/⫹ astrocytes (Fig. 7C), compared to the cytoplasmic localization of STI1 in wild-type astrocytes. Subcellular fractionation confirmed increased STI1 localization in the nucleus of STI1⫺/⫹ astrocytes (Supplemental Fig
8
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S2A, B). Decreased levels of STI1 in STI1⫺/⫹ astrocytes
did not affect cell cycle (Supplemental Fig. S2C, D)
or astrocyte proliferation (Supplemental Fig. S2E–
G). However, in agreement with the data obtained
with MEFs, mutant astrocytes presented an increase
in foci number per cell, detected by ␥-H2AX staining
(Fig. 7D).
To examine whether reduced levels of STI1 affects
the capacity of mice to respond to cellular stress and
injury, we used a model of ischemic insult. We submitted STI1⫺/⫹ and wild-type mice to the middle cerebral
artery occlusion (MCAO, 60 min) technique to induce
unilateral stroke. Sham-operated mice from both genotypes showed no signs of stroke and survived well after
the surgery, independent of genotype (Fig. 8A). We
detected no differences between genotypes in physiological parameters due to MCAO (Table 2). Whereas
most wild-type mice survived after stroke injury (20%
lethality rate), STI1⫺/⫹ mice, however, displayed increased mortality and nearly 50% of the mice died 5 d
following surgery (Fig. 8A). STI1 mutant mice showed
increased brain infarct volume when compared to
wild-type mice 24 h following MCAO (Fig. 8B). We
tested whether STI1⫺/⫹ mice that survived the stroke
injury recovered similarly to wild-type mice. Both genotypes lost weight just after surgery, but recovered after 7
d (Fig. 8C). Interestingly, behavioral analysis demonstrated that 7 d after MCAO, STI1⫺/⫹ mice performed
poorly compared to wild-type mice in the tape removal
test used to evaluate fine sensorimotor function (28).
Both genotypes showed a clear deficit to perceive and
remove the tape in the contralateral (right paw, RP),
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Figure 6. Rescue of embryonic lethality of STI1⫺/⫺ mice by transgenic expression of
STI1. A) Number of copies of the STI1 gene in genomic DNA from STI1⫹/⫹ (n⫽8) and
STI1⫺/⫹ mice (n⫽4), as well as transgenic mouse lines STI1-TgA (n⫽4) and STI1-TgC
(n⫽5). B) STI1 mRNA expression in the brain of STI1⫹/⫹ mice (n⫽9) and transgenic
lines STI1-TgA (n⫽4) and STI1-TgC (n⫽4). C) Representative immunoblotting and
STI1 protein expression quantification in the brain of ST1⫹/⫹ (n⫽4) and STI1-TgA
mice (n⫽4). D) Representative immunoblotting and STI1 protein expression quantification in the brain of ST1⫹/⫹ (n⫽4) and STI1-TgC mice (n⫽4 mice). E) qPCR to
determine the number of copies of the STI1⫺ allele (which is absent in wild-type mice)
in tissue from adult mice, showing that expression of BAC-STI1 allowed survival of STI1⫺/⫺ mice (4 STI1⫹/⫹, 11 STI1⫺/⫹,
and 5 TgASTI1⫺/⫺). Results are presented as means ⫾ se; data were analyzed and compared by 1-way ANOVA and
Newman-Keuls post hoc test (A, B), Student’s t test (C, D), and 2 test (P⬍0.05 from the expected distribution; E). **P ⬍
0.001, ***P ⬍ 0.0001.

but not in the ipsilateral (left paw, LP) ischemic side
(Fig. 8D), indicating a functional deficit due to ischemia. However, STI1⫺/⫹ mice showed decreased dexterity in their RP compared to wild-type controls to
remove the tape (Fig. 8E). These experiments indicate
that decreased STI1 levels affect brain injury after
ischemic stroke, survival of animals, and their functional recovery.
To establish potential mechanisms by which STI1
may affect neuronal function after stroke, we examined
the response of astrocytes and neuronal cultures to
OGD. We found that intracellular STI1 was reduced in
STI1⫹/⫹ astrocytes after OGD (Fig. 9A). In STI1⫺/⫹
astrocytes, the intracellular levels of STI1 were further
reduced by OGD. Experiments using proteasome in-

hibitors indicated that reduced levels of STI1 were not
due to increased protein degradation (not shown),
suggesting the possibility of changes in secretion. Indeed, wild-type astrocytes increased STI1 secretion by
close to 3-fold after OGD (Fig. 9B). Although astrocytes
derived from STI1⫺/⫹ mice also showed increased
secretion of STI1 following OGD, the levels of extracellular STI1 were, as expected, ⬃2-fold lower than those
of wild-type astrocytes (Fig. 9B). Therefore, as a consequence of ischemia, astrocytes secrete significant
amounts of STI1, (Fig. 9A, B); however, since STI1⫺/⫹
astrocytes have 50% less protein, the amount of STI1
secreted by these mutated cells is lower. OGD did not
increase cell death of astrocytes from either genotype
(Fig. 9C).

Figure 7. STI1 secretion, expression, and cellular localization in STI1⫹/⫹ and STI1⫺/⫹ astrocyte cultures. A) STI1 expression
in STI1⫹/⫹ and STI1⫺/⫹ astrocytes (cultures obtained from 4 embryos/genotype). B) Detection of STI1 in CM from astrocytes
(cultures obtained from 5 embryos/genotype). C) Immunofluorescence showing a reduction of STI1 labeling and localization
of STI1 in STI1⫹/⫹ and STI1⫺/⫹ astrocytes (top panel) and quantification of cells with nuclear STI1 (bottom panel). Scale bars ⫽
15 m. D) Top panel: immunofluorescence for STI1 expression (green) and labeling of ␥-H2AX (red) in STI1⫹/⫹ and STI1⫺/⫹
astrocytes. Scale bars ⫽ 30 m. Bottom panel: quantification of number of foci per cell (cultures obtained from 7
embryos/genotype). Results are presented as means ⫾ se. *P ⬍ 0.01; Student’s t test.
STI1 AND CELLULAR STRESS
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Figure 8. Regulation of functional recovery in ischemia by STI1. A) Survival curve of STI1⫹/⫹ and STI1⫺/⫹ mice submitted to
60 min of unilateral ischemia (MCAO). B) Representative MR images and group analyses of infarct volume in brains of STI1⫹/⫹
(n⫽6) and STI1⫺/⫹ mice (n⫽5). C) Weight of mice submitted to MCAO (n⫽6 Sham STI1⫹/⫹, n⫽5 Sham STI1⫺/⫹, n⫽9
STI1⫹/⫹, n⫽7 STI1⫺/⫹). D) Functional recovery of STI1⫹/⫹ and STI1⫺/⫹ mice submitted to MCAO, determined at d 7 after
stroke using the tape removal test. Time to perceive the tape in the right paw (RP) or left paw (LP) (n⫽9 STI1⫹/⫹, n⫽7
STI1⫺/⫹). E) Identical to D, but showing the time to remove the tape. Results are presented as means ⫾ se; data were analyzed
and compared by 1-way ANOVA and Newman-Keuls post hoc test, Student’s t test, and Mantel-Cox log-rank test (P⫽0.0002; A).
*P ⬍ 0.01 vs. control mice.

In cultured primary neurons, 1 h OGD caused increased cell death (Fig. 9D), an effect that was similar in
both control and STI1⫺/⫹ neurons. Hence, changes in
intracellular levels of STI1 did not seem to affect the
survival of neurons. To mimic the secretion of STI1
from astrocytes, we treated neurons with recombinant
STI1, which reproduces the effects of astrocyte-secreted
protein (40). Treatment of neurons from both genotypes with extracellular recombinant STI1 attenuated
neuronal death in response to OGD (Fig. 9D), suggest-

ing that rather than intracellular STI1, it is the extracellular protein that protects neurons from ischemic
injury.
PrPC, an STI1-interacting protein, plays a role in
ischemic injury and increased levels of PrPC seem to
protect, whereas lack of PrPC exacerbates neuronal
injury in response to ischemic insults in vivo (41– 43).
To investigate the possibility that extracellular STI1
protects neurons via a PrPC-dependent pathway in
neurons, we repeated these experiments using neurons

TABLE 2. Physiological measurements before and during MCAO
Measurement

Before MCAO
Heart rate (beats/min)
Arterial blood pH
Oxygen saturation (%)
Temperature (°C)
Glucose (mM)
During MCAO
Heart rate (beats/min)
Arterial blood pH
Oxygen saturation (%)
Temperature (°C)
Glucose (mM)

STI1⫹/⫹

STI1⫺/⫹

697.4 ⫾ 43.8 (n⫽9)
7.193 ⫾ 0.003 (n⫽3)
99.37 ⫾ 3.74 (n⫽3)
35.90 ⫾ 0.30 (n⫽3)
8.067 ⫾ 0.633 (n⫽3)

669.2 ⫾ 34.8 (n⫽9)
7.233 ⫾ 0.007 (n⫽3)
97.80 ⫾ 5.8 (n⫽3)
36.20 ⫾ 0.36 (n⫽3)
8.833 ⫾ 0.033 (n⫽3)

693.1 ⫾ 42.9 (n⫽6)
7.107 ⫾ 0.0201 (n⫽6)
99.32 ⫾ 3.47 (n⫽6)
34.35 ⫾ 0.43 (n⫽6)
10.03 ⫾ 1.73 (n⫽6)

693.1 ⫾ 55.9 (n⫽4)
7.100 ⫾ 0.044 (n⫽4)
73.55 ⫾ 10.31 (n⫽4)
34.65 ⫾ 0.52 (n⫽4)
9.650 ⫾ 1.707 (n⫽4)

Values are expressed as means ⫾ SE. MCAO, middle cerebral artery occlusion.

10

Vol. 27

September 2013

The FASEB Journal 䡠 www.fasebj.org

BERALDO ET AL.

Figure 9. STI1 rescues neurons from
OGD-induced cell death. A) Intracellular
STI1 in astrocytes obtained from protein
extracts after 0 or 9 h of OGD (protein
extract from independent cultures from
6 embryos/genotype). **P ⬍ 0.001 vs. 0 h
of OGD in wild-type mice. B) STI1 secretion from astrocytes in response to 9 h
OGD (CM from independent cultures
from 6 embryos/genotype). ***P ⬍
0.0001 vs. all other conditions. C) Cell
death in astrocytes exposed to OGD for 3,
6, and 9 h (independent cultures obtained from 5 embryos/genotype). D) Cell death induced by 1 h OGD in STI1⫹/⫹ and STI1⫺/⫹ neurons treated or not with
recombinant STI1 (1 M) 1 h prior to OGD (independent cultures obtained from 6 embryos/genotype). **P ⬍ 0.001, ***P ⬍
0.0001 vs. STI1 treatment or neurons without OGD. E) Cell death induced by 1 h OGD in wild-type and Prnp0/0 neurons
treated or not with recombinant STI1 (1 M) 1 h prior to OGD (independent cultures obtained from 4 embryos/
genotype). Results are presented as means ⫾ se; data were analyzed and compared by 1-way ANOVA and Newman-Keuls
post hoc test. ***P ⬍ 0.0001 vs. neurons without OGD treatment or wild-type neurons treated with STI1 after OGD.

of PrPC-null mice (Prnp0/0). The neuroprotective effect
of STI1 was prevented in neurons from PrPC-null mice
(Fig. 9E), suggesting that activation of PrPC by STI1
plays a role in protecting neurons against ischemic
insult.

DISCUSSION
The present experiments demonstrate that Stip1 shows
characteristics of a maternal (oogenetic)-effect gene,
playing critical roles during development in mammals.
STI1⫺/⫺ blastocysts obtained from STI1⫹/⫺ intercrosses were observed at 50% of the expected mendelian frequency, suggesting that blastocysts originating
from zygotes lacking sufficient maternally inherited
STI1 may not survive. Interestingly, surviving STI1⫺/⫺
blastocysts showed immunostaining for STI1, suggesting the possibility that part of the blastocyts may have
received sufficient maternally inherited STI1 to allow
development of embryos. It would be of interest to
define the precise mechanism by which maternally
derived STI1 is transferred to blastocysts. Embryonically
expressed STI1 is critical in later stages of development,
as mutant embryos could not survive past E10.5. We
show that maternal STI1 protein might be transferred
to embryos in later stages of development, as we could
detect small amounts of STI1 immunoreactivity in
E10.5 embryos, likely due to placental disruption. Notably, we did not detect STI1 mRNA in STI1⫺/⫺ E10.5
STI1 AND CELLULAR STRESS

embryos, indicating lack of embryonic STI1 protein
synthesis. The rescue of lethality by transgenic BAC
expression supports the notion that STI1 has unique
roles during development and that maternally transferred STI1 cannot support embryonic development.
Embryonic lethality is commonly associated with placental dysfunction in the E9 –E12 stage. Interestingly,
Hsp90␤-knockout mice (44), but not Hsp90␣-knockout
mice (45), present disrupted placenta. Hence, placental disruption may also contribute to embryonic lethality in STI1 mutant embryos.
Despite recent insights from structural models of
STI1 interaction with Hsp70 and Hsp90 demonstrating
STI1 regulation of client recruitment (7, 46 – 48), it is
unknown whether STI1 has unique or overlapping
roles in mammals in vivo. Our data suggest that loss of
embryonic STI1 is not tolerated during development,
and cells present decreased resilience to stress, showing
increased DNA damage and cell death. Hence, other
cochaperones do not seem to be able to compensate
for the loss of STI1. These results contrast with those of
mice deficient for p23, another Hsp90 chaperone,
which present perinatal lethality specifically related to
skin and lung development (49), suggesting distinct
requirements for different cochaperones during development.
The early effects of STI1 in embryogenesis are compatible with its regulation of stem cell self-renewal (50).
Interestingly, Hsp90 and, more recently, STI1 have
11

been shown to regulate epigenetic programs and transposon silencing via piRNAs in Drosophila (8, 51). Remarkably, maternal STI1 appears to influence canalization in Drosophila via the Piwi pathway (8). Future
studies aimed at further defining these mechanisms
may provide novel insight in mammalian embryonic
development.
We show that STI1 has a critical role in cellular
survival. This conclusion is supported by the increased
cell death in embryos and the inability to maintain
STI1⫺/⫺ MEFs in culture. Because of the early death
that we observed in blastocysts, as well as the inability of
mutant cells to survive, we favor the possibility that the
placental defect that we identified contributes to, but it
is not the only cause of, cellular death in these mutant
embryos. These effects of Stip1 seem to depend, at least
in part, on intracellular STI1, as we were unable to
rescue STI1⫺/⫺ MEFs using recombinant extracellular
STI1, but could rescue STI1⫺/⫺ mice by transgenic
expression of a BAC containing Stip1. The increase in
foci number in STI1⫺/⫺ MEFs indicates that lack of
chaperone activity may affect DNA damage response.
Interestingly, Hsp90, which is regulated by STI1, has
been previously implicated in the DNA damage response (52–55). By targeting STI1, we likely affected
the functions of a wide range of Hsp90/Hsp70 client
proteins (56 –58). Indeed, this seems to be the case,
given that three known Hsp90 clients (59 – 61) show
reduced levels in STI1-mutant mice, even though
Hsp90 levels were unaffected. In contrast with Hsp90
and Hsp70 that have different isoforms, there are no
known homologs for Stip1, which may explain why we
observed such striking phenotype during development.
Given the very large number of Hsp90 client proteins
(5, 56, 57), it is unlikely that the phenotypes that we
uncovered are related to one specific client. It is also
unclear whether the remaining amounts of Hsp90
client proteins in STI1 mutant embryos are functional.
Hence, inhibitors of STI1 may have more widespread
effects in mammals than inhibitors of Hsp90. Indeed, a
recent report demonstrates that inhibition of STI1
interaction with Hsp90 by drugs is effective to kill
cancer cells (62).
Our experiment using a stroke model supports an
important role for endogenous STI1 in the recovery
from ischemic injury in vivo. PrPC expression has been
shown to protect the brain following ischemic insults,
and lack of PrPC leads to an increase in neuronal injury
in stroke models (41, 42, 63). However, the exact
mechanisms by which PrPC influences outcomes in
stroke are unknown. We now show that OGD, used as
an in vitro model of ischemic insult, can increase
secretion of STI1 from astrocytes and that secretion
from STI1⫺/⫹ astrocytes is decreased in this condition.
Our experiments using cultured neurons suggest that
the increased sensitivity observed in vivo in STI1⫺/⫹
mice may not be related to decreased intracellular
levels of STI1 in neurons, as both control and STI1⫺/⫹
neurons responded similarly to OGD. In these neuronal cultures, extracellular STI1 was able to provide
12
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neuroprotection for OGD-induced neuronal death.
Moreover, this effect of STI1 was strictly dependent on
the presence of PrPC in neurons. These results expand
previous observations in which STI1 was shown to
prevent neuronal death induced by staurosporine (14,
17) to demonstrate a role for this secreted cochaperone
in a pathological relevant insult, ischemic injury. Our in
vitro data with recombinant STI1 and in vivo with
STI1⫺/⫹ mice suggest that lack of STI1-mediated signaling may underlie the increased sensitivity of PrPCnull mice to ischemic injury.
Our experiments provide novel evidence that STI1
plays a unique and nonoverlapping role as a cochaperone during embryonic development and in cellular
survival, suggesting that loss of STI1-regulated chaperone activity is not tolerated. Our data also support a
role for STI1 in neuroprotection against ischemic insult, by a mechanism involving increased secretion
from astrocytes and activation of PrPC. Hence, STI1 is a
stress-response protein that presents multiple intracellular and extracellular roles with unique properties for
protection of cells against stress.
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